We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Antimicrobial Susceptibility for Helicobacter Pylori Eradication

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2011 by LUIS BUJANDA, Hospital Donostia.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01486082
First Posted: December 6, 2011
Last Update Posted: December 13, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
LUIS BUJANDA, Hospital Donostia
  Purpose
Due to the high rate of resistance to clarithromycin in our area the investigators proposed an study to assess the need of antibiogram previous to the empirical OCA 10 treatment, in order to improve the rate of eradication.

Condition Intervention Phase
Helicobacter Pylori Infection Other: OCA 10 Phase 4

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Usefulness of Antimicrobial Susceptibility in the Eradication of Helicobacter Pylori

Resource links provided by NLM:


Further study details as provided by LUIS BUJANDA, Hospital Donostia:

Primary Outcome Measures:
  • Number of patients in whom Helicobacter pylori was eradicated. [ Time Frame: 9 months ]
    The investigators will measure the rate of eradication in each gruop after OCA treatment. One group receive OCA without antibiogram and the other one after checking the sensitivity to clarithromycin.


Secondary Outcome Measures:
  • Number of patient with adverse event [ Time Frame: 9 months ]
  • Cost of the eradication of Helicobacter Pylori in each group. [ Time Frame: 9 months ]

Estimated Enrollment: 1
Study Start Date: February 2011
Estimated Study Completion Date: May 2012
Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Empirical OCA
This group will be treated with omeprazole, amoxicillin and clarithromycin without having a previous antibiogram.
Other: OCA 10
A group will be treated with omeprazole (20 mg / 12 h), amoxicillin (1 g/ 12 h)and clarithromycin (500 mg/12 h) for 10 days (as following current guides) without having a previous antibiogram, and the other group will be treated after antibiotic susceptibility.
Other Names:
  • O: Omeprazole
  • C: Clarithromycin
  • A: Amoxicillin
OCA after antibiogram
This group will be treated with omeprazole, clarithromycin and amoxicillin after an antibiotic susceptibility confirmation.
Other: OCA 10
A group will be treated with omeprazole (20 mg / 12 h), amoxicillin (1 g/ 12 h)and clarithromycin (500 mg/12 h) for 10 days (as following current guides) without having a previous antibiogram, and the other group will be treated after antibiotic susceptibility.
Other Names:
  • O: Omeprazole
  • C: Clarithromycin
  • A: Amoxicillin

Detailed Description:

Usefulness of antimicrobial susceptibility in the eradication of Helicobacter pylori

PURPOSE

Background:

  • The rate of eradication of Helicobacter pylori with standard triple therapy (OCA: omeprazole + clarithromycin + amoxicillin) in our area is less than the expected according to the III Maastricht III consensus. However, the current guidelines recommend the use of this therapy.
  • According to the Maastricht III consensus, in populations with high rates of clarithromycin resistance (15-20%) another therapy should be considered, or alternatively, testing antimicrobial susceptibility of the H. pylori prior to treatment.

Objectives:

  • To clarify the real rate of eradication with OCA therapy with and without antimicrobial susceptibility in our area (with high rate of resistance to clarythromycin).
  • To study which is the diagnostic-therapeutic strategy more cost-effective for the treatment of H. pylori.

Design:

  • Participants will be screened with a full medical history.
  • Participants will aleatory receive OCA therapy empirically, or after antimicrobial susceptibility test if there is no resistance to clarythromycin, for ten days.
  • In all cases the eradication of H. pylori will be checked by 13C urea breath test (UBT) in 8 weeks after the therapy have been finished.
  • All the adverse event of the therapy will be reported.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
The investigators recruited patients who are diagnosed with helicobacter pylori infection in our hospital (Hospital Donostia) or in any of the specialist care centres under the management of the Hospital Donostia.
Criteria

Inclusion Criteria:

  • Diagnosis of H. pylori infection provided by culture, histology or UBT.
  • Patients need and indication to treat (peptic ulcer disease, firs-degree family history of gastric cancer, MALT lymphoma or dyspeptic symptoms)
  • Patients must be 18 years or older.

Exclusion criteria:

  • Previous treatment for H. pylori eradication.
  • Patients who have severe concomitant disease.
  • Patients who have previous gastric surgery.
  • Patients who have intolerance to any antimicrobial drugs.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01486082


Contacts
Contact: LUIS BUJANDA, Dr. 943 00 7173 luis.bujandafernandezdepierola@osakidetza.net

Locations
Spain
Hospital Donostia Recruiting
San Sebastian, Guipuzcoa, Spain, 20014
Contact: LUIS BUJANDA, Dr    943 007173    luis.bujandafernandezdepierola@osakidetza.net   
Contact: MAIDER MARTOS, Dr.    943 00 7173    maider.martosmartin@osakidetza.net   
Principal Investigator: LUIS BUJANDA, Dr.         
Sponsors and Collaborators
Hospital Donostia
Investigators
Study Director: LUIS BUJANDA
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: LUIS BUJANDA, Director, Head of Gastroenterology Department, principal investigator, clinical proffesor, Hospital Donostia
ClinicalTrials.gov Identifier: NCT01486082     History of Changes
Other Study ID Numbers: HP02
First Submitted: November 19, 2011
First Posted: December 6, 2011
Last Update Posted: December 13, 2011
Last Verified: December 2011

Keywords provided by LUIS BUJANDA, Hospital Donostia:
OCA 10
Antibiogram
Eradication

Additional relevant MeSH terms:
Disease Susceptibility
Helicobacter Infections
Disease Attributes
Pathologic Processes
Gram-Negative Bacterial Infections
Bacterial Infections
Amoxicillin
Clarithromycin
Anti-Bacterial Agents
Anti-Infective Agents
Omeprazole
Anti-Ulcer Agents
Gastrointestinal Agents
Proton Pump Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Protein Synthesis Inhibitors
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 Enzyme Inhibitors